Blog

David Sebag: The first patient was randomised in the ARTEMIS organ preservation phase II rectal cancer trial at Leeds Teaching Hospitals

Photo taken from David Sebag-Montefiore/LinkedIn

Apr 1, 2024, 09:54

David Sebag: The first patient was randomised in the ARTEMIS organ preservation phase II rectal cancer trial at Leeds Teaching Hospitals

David Sebag, Professor of Clinical Oncology and Health Research at University of Leeds, shared on X:

“Fantastic news! Following last week’s brilliant hybrid workshop at University of Leeds, the first patient was randomised in the ARTEMIS organ preservation phase II rectal cancer trial at Leeds Teaching Hospitals today!
Huge congrats to the team!

ARTEMIS will test the benefits of adding Adlai Nortye AN0025 to short course and long course CRT. It is a selective inhibitor of EP4, one of four PGE2 receptors, a strong pre-clinical rationale and a high CR rate in early phase.
doi: 10.1016/j.radonc.2023.109669

You can read more about this study here.”

Source: David Sebag/X

Adlai Nortye ARTEMIS cancer CRT David Sebag Leeds Teaching Hospitals OncoDaily Oncology PGE2 receptors rectal cancer selective inhibitor of EP4 Trial University of Leeds

Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 10

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Richard Sullivan: Do we need a 'new' Geneva Convention and protocols?

Remembering Virgil Abloh: Louis Vuitton’s Creative Director Honored at 41 After His Brave Battle with Cardiac Angiosarcoma

Special Coverage